Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy

• DOI: 10.3389/fphar.2023.1326281
• Publication Date: 2024-01-03T04:13:42Z
• Authors: Xiao-Huan Wei; Yuan-Yuan Liu
• Keywords: Janus kinase 2

Disturbances in immunoregulation may lead to both cancer and autoimmune diseases. Many therapeutic drugs for diseases also display anti-tumor efficacy. The Janus kinase/signal transducer activator of transcription signaling pathways are involved the secretion more than 50 distinct cytokines, which have critical roles inducing tumorigenesis. Thus, kinases become classical immunotherapeutic targets immune disease. More 70 kinase inhibitors been approved as immunomodulatory clinical use, 12 used treatment This systematic review aims elucidate role clinically that were primarily designed their potential translation treatments.